Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

clear Found 205 recommendations for 65 medicines and 3 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
8.2. Antineoplastics and supportive medicines
  1. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  2. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  3. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  4. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg tablet; 300 mg tablet
    Indications
    Tumour lysis syndrome
  5. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Malignant neoplasms of breast Other specified malignant neoplasms of breast
  6. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  7. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, NOS
  8. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  9. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  10. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Hodgkin lymphoma Kaposi sarcoma of unspecified primary site
  11. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  15. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  18. Cytarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    Indications
    Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, NOS Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia
  19. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  20. Dactinomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 µg in vial powder for injection
    Indications
    Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  21. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, NOS
  22. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, NOS Myeloid leukaemia
  23. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, NOS
  24. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
    Indications
    Malignant neoplasms of prostate Other specified malignant neoplasms of breast Malignant neoplasms of breast
  26. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  28. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropenias
  29. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  31. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  32. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  33. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, NOS
  34. Hydroxycarbamide General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    Indications
    Chronic myeloid leukaemia, NOS
  35. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Ewing sarcoma of bone and articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site
  36. Imatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg tablet; 400 mg tablet
    Indications
    Gastrointestinal stromal tumour of unspecified gastrointestinal sites Chronic myeloid leukaemia, NOS
  37. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine
  38. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  39. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of prostate Malignant neoplasms of breast
  40. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  41. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg tablet
    Indications
    Lymphoid leukaemia, NOS Acute myeloid leukaemia with recurrent genetic abnormalities
  44. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, NOS
  45. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
    Indications
    Chronic myeloid leukaemia, NOS
  46. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Melanoma of skin
  47. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  49. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial
    Indications
    Lymphoid leukaemia, NOS
  50. Pembrolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin
  52. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
    Hodgkin lymphoma
  53. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  54. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas
  55. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  56. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  57. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, NOS
  58. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  59. Vinblastine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
    Indications
    Hodgkin lymphoma Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of the ovary Germ cell tumour of testis
  61. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    Indications
    Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast
  62. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow